Balance Sheet
AssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Accumulated Expenses (2019 - 2024)

Benitec Biopharma's Accumulated Expenses history spans 7 years, with the latest figure at $426000.0 for Q1 2025.

  • For Q1 2025, Accumulated Expenses changed N/A year-over-year to $426000.0; the TTM value through Mar 2025 reached $426000.0, changed N/A, while the annual FY2024 figure was $475000.0, 0.64% up from the prior year.
  • Accumulated Expenses for Q1 2025 was $426000.0 at Benitec Biopharma, down from $537000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $537000.0 in Q4 2024 and bottomed at $231000.0 in Q1 2021.
  • The 5-year median for Accumulated Expenses is $413000.0 (2022), against an average of $405250.0.
  • The largest annual shift saw Accumulated Expenses soared 54.55% in 2022 before it increased 0.64% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $321000.0 in 2021, then grew by 23.36% to $396000.0 in 2022, then soared by 32.07% to $523000.0 in 2023, then rose by 2.68% to $537000.0 in 2024, then fell by 20.67% to $426000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Accumulated Expenses are $426000.0 (Q1 2025), $537000.0 (Q4 2024), and $495000.0 (Q3 2024).